New Indication: Pembrolizumab for Early-Stage NSCLC
Study
A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671)
|
Resectable, early stage (stage II and III) NSCLC
|
Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (n=397)
|
Arm B: ChemtherapyS->PBO (n=400)
|
|
Efficacy
• mEFS: NR vs 17.0 ms, HR:0.58, p<0.001
|
24 mos EFS: 62.4% vs 40.6%
|
mOS: NR vs. 45.5 mos, p=0.02 (NS)
|
24 mos OS: 80.9% vs. 77.6%
|
mPR: 30.2% vs 11.0%, p<0.001
|
PcR: 18.1% vs. 4.0%, p=0.0001
|
Safety
Grade3: Neutropenia (20.7% vs.19%), anemia (7.3% vs. 5.5%)
|
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023
